سعر ريسبيردال كونستا 37.5 مجم 2024

Risperidone 37.5 mg long-acting injectable (microspheres) vial for intramuscular use every 2 weeks (Janssen-Cilag; Vetter Pharma listed as manufacturer).

• Treatment of schizophrenia.DailyMed (U.S. National Library of Medicine)
• Maintenance treatment of Bipolar I Disorder, as monotherapy or adjunctive to lithium or valproate.DailyMed (U.S. National Library of Medicine)

• Schizophrenia 12-week trial (25/50 mg): reactions in >=2% included constipation, dyspepsia, dry mouth, salivary hypersecretion, blurred vision, fatigue and parkinsonism. Bipolar maintenance monotherapy: weight increased (5%), dizziness and hypertension (3%).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to risperidone, paliperidone or any excipient of the formulation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increased mortality in elderly patients with dementia-related psychosis; not approved for dementia-related psychosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Warnings include neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, hyperprolactinaemia, orthostatic hypotension, falls, leukopenia/neutropenia/agranulocytosis, seizures, dysphagia, priapism, body-temperature dysregulation, and care to avoid inadvertent injection into a blood vessel.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Carbamazepine and other CYP3A4 inducersMay decrease risperidone + 9-hydroxyrisperidone concentrations; monitor closely during the first 4-8 weeks after starting an inducer and re-evaluate (possibly lower) the dose when it is stopped.DailyMed (U.S. National Library of Medicine)

• Published epidemiologic data have not established a drug-associated risk of major birth defects, miscarriage or adverse maternal/fetal outcomes; untreated schizophrenia or bipolar I disorder carries maternal risk. A pregnancy exposure registry exists.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Risperidone and 9-hydroxyrisperidone pass into breast milk (relative infant dose 2.3-4.7%); sedation, failure to thrive, jitteriness and extrapyramidal symptoms reported in breastfed infants; monitor exposed infants. Risperidone is detectable in plasma up to 8 weeks after a single Consta dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Risperidone: Mechanism unclear; therapeutic activity may be mediated through combined dopamine D2 and serotonin 5-HT2 receptor antagonism (US label).